Therapeutic Hotline: Cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis

Dermatol Ther. Jan-Feb 2010;23(1):90-3. doi: 10.1111/j.1529-8019.2009.01295.x.

Abstract

Leukotrienes are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase pathway. Experimental data suggest a role for cysteinyl leukotrienes in the pathogenesis of atopy giving a rationale for its use in asthma, allergic rhinitis, and chronic urticaria management. A few clinical observations and small trials suggest that montelukast may be used in an adjunctive manner as an effective therapeutic option for all age categories affected by moderate-to-severe atopic dermatitis. Our own observations proved that montelukast as a prospective corticosteroid-sparing option in the complex therapeutic strategy of corticosteroid-dependent atopic dermatitis patients, even in the severe erythrodermic cases.

Publication types

  • Case Reports

MeSH terms

  • Acetates / therapeutic use*
  • Adult
  • Asthma / drug therapy
  • Dermatitis, Atopic / drug therapy*
  • Eosinophilia / drug therapy
  • Exudates and Transudates / drug effects
  • Female
  • Humans
  • Immunoglobulin E / blood
  • Leukotriene Antagonists / therapeutic use*
  • Male
  • Methylprednisolone / therapeutic use
  • Quinolines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Receptors, Leukotriene / metabolism
  • Rhinitis / drug therapy
  • Treatment Outcome
  • Young Adult

Substances

  • Acetates
  • Leukotriene Antagonists
  • Quinolines
  • Receptors, Leukotriene
  • Immunoglobulin E
  • leukotriene D4 receptor
  • montelukast
  • Methylprednisolone